BioAge Labs, Inc.
Close on Oct 19, 2026
- Market cap
- $223.75M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $2.40M | $-0.58 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 8, 2026 | Before market open | $2.80M | $-0.52 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 24, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $2.10M | $-0.56 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $2.41M | $-0.60 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | $-6.70 | – |
Press releases
Announcements BioAge Labs filed with the SEC
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
BioAge announces indication expansion for oral NLRP3 inhibitor BGE-102, with plans to initiate Phase 1b/2a proof-of-concept clinical trial in patients with diabetic macular edema in mid-2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business
Results of operations · EX-99.1 to Form 8-K
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business
Results of operations · EX-99.1 to Form 8-K
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business
Results of operations · EX-99.1 to Form 8-K
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Results of operations · EX-99.1 to Form 8-K
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business
Results of operations · EX-99.1 to Form 8-K